These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2358293)

  • 21. Evidence for octreotide subcutaneously in the treatment of acromegaly.
    Liuzzi A; Oppizzi G
    J Endocrinol; 1997 Oct; 155 Suppl 1():S61-5. PubMed ID: 9389999
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of medical therapy in the management of acromegaly.
    Vance ML; Laws ER
    Neurosurgery; 2005 May; 56(5):877-85; discussion 877-85. PubMed ID: 15854234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective treatment of recurrent acromegaly with a long-active somatostatin analogue (sandostatin).
    Miranda R; Zárate A; Ruíz Velasco G
    Arch Invest Med (Mex); 1988; 19(4):445-8. PubMed ID: 3245759
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of therapy-resistant acromegaly using Sandostatin].
    von Werder K; Mehltretter G; Müller OA
    Z Gastroenterol; 1990 Sep; 28 Suppl 2():29-31. PubMed ID: 1980775
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New perspectives in the medical treatment of acromegaly.
    Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
    J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of acromegaly with a long-acting synthetic analog of somatostatin].
    Miranda R; Ruíz-Velasco G; Zárate A
    Arch Invest Med (Mex); 1988; 19(2):113-8. PubMed ID: 3228344
    [No Abstract]   [Full Text] [Related]  

  • 29. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients.
    Gatta B; Hau DH; Catargi B; Roger P; Tabarin A
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):477-8. PubMed ID: 16181243
    [No Abstract]   [Full Text] [Related]  

  • 30. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
    Samson SL
    Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatostatin receptor ligands in the treatment of acromegaly.
    Gadelha MR; Wildemberg LE; Bronstein MD; Gatto F; Ferone D
    Pituitary; 2017 Feb; 20(1):100-108. PubMed ID: 28176162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis.
    Gurel MH; Han Y; Stevens AL; Furtado A; Cox D
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):22. PubMed ID: 28372573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging.
    Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
    Pituitary; 2007; 10(3):233-6. PubMed ID: 17541750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of the efficacy of Octreotide LAR in the treatment of acromegaly--a yearly observation].
    Bałdys-Waligórska A; Gołkowski F; Krzentowska A; Sokołowski G; Hubalewska-Dydejczyk A
    Przegl Lek; 2009; 66(5):218-21. PubMed ID: 19739577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
    Mattar P; Alves Martins MR; Abucham J
    Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New medical therapies on the horizon: oral octreotide.
    Biermasz NR
    Pituitary; 2017 Feb; 20(1):149-153. PubMed ID: 28091879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
    Andries M; Glintborg D; Kvistborg A; Hagen C; Andersen M
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):473-80. PubMed ID: 17941902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
    van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.